Lucentis FDA Approved to Treat Diabetic Macular Edema

The FDA has approved Lucentis (Ranibizumab) to treat diabetic macular edema as a monthly injection, making it the first drug approved to treat the condition. The 0.3mg one time dosage that has been approved is estimated to cost roughly $1,170.  The newly approved drug has been shown to be quite efficacious in improving vision in those patients suffering from diabetic macular edema which has served to strengthen its claim for approval.

To read the full story check the AOA News Blog.

Scroll to Top